New patent issued for core rare disease target indication for crofelemer

Napo has approximately 230 patents issued and pending

Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025

• Company to Share New Vision for Growth

• Update on steps to realign and simplify its business structure, bring a stronger focus to serving customers, enable a more competitive cost model, and better position the company for future growth and improved profitability

Assays Confirm Mineralization Across Entire 79 m trench, Including 4 m Averaging 4.52g/t Au

Company provides update on regulatory progress towards US NDA submission

Includes 0.4 m @ 44.4 g/t Gold, 0.6 m @ 14.6 g/t Au, and 0.2 m @ 29.0 g/t Au